Abstracts tagged "ANCA"

Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Sohail Farshad¹, Alexandra Halalau ², Sayf Al-Katib ³, Julie George ⁴ and Elena Schiopu ⁵, ¹Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, ³Department of Radiology, Beaumont Health System, Royal Oak, MI, ⁴Beaumont Health System, Royal Oak, MI, ⁵Department of Rheumatology, University of Michigan, Ann Arbor
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…
Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Sana Afroz¹ and Najia Shakoor ², ¹RUMC, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality. In addition, maintenance…
Abstract Number: 1672 • 2019 ACR/ARP Annual Meeting
Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018
Arielle Mendel¹, Simon Carette ² and Christian Pagnoux ², ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
Background/Purpose: Rituximab (RTX) is an effective therapy for ANCA-Associated Vasculitis (AAV). The Canadian Vasculitis Research Network (CanVasc) recommends RTX for induction among patients with unacceptable risk…
Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting
Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis
Audrey Hopkins¹, Stanley Chu ², Philip Seo ³, Eric Gapud ¹, Brendan Antiochos ¹, Shaker Eid ¹, Jason Liebowitz ¹ and Duvuru Geetha ¹, ¹Johns Hopkins Bayview Medical Center, Baltimore, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…
Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Paul Brogan¹, Gavin Cleary², Aimee O. Hersh³, Ozgur Kasapcopur⁴, Satyapal Rangaraj⁵, Rae S.M. Yeung⁶, Andrew Zeft⁷, Simone Melega⁸, Paul Brunetta⁹, Jennifer Cooper¹⁰, Pooneh Pordeli¹¹ and Patricia B. Lehane¹², ¹Infection Inflammation and Rheumatology, UCL GOL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Alder Hey Children's Hospital, Liverpool, United Kingdom, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁵Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁶Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁷Center for Pediatric Rheumatology & Immunology, The Cleveland Clinic Foundation, Cleveland, OH, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰Pediatric Rheumatology, Univ. of California San Francisco, San Francisco, CA, ¹¹Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…
Abstract Number: 1752 • 2018 ACR/ARHP Annual Meeting
Asthma in Eosinophilic Granulomatosis with Polyangiitis Treated with Rituximab
Marta Casal Moura¹, Alvise Berti², Karina Keogh², Gerald Volcheck³, Ulrich Specks⁴ and Misbah Baqir⁵, ¹Pulmonary and Critical Care, Thoracic Disease Research Unit, Mayo Clinic College of Medicine, Rochester, MN, ²Pulmonary and Critical Care, Mayo Clinic College of Medicine, Rochester, MN, ³Allergic Diseases, Internal Medicine Department, Mayo Clinic College of Medicine, Rochester, MN, ⁴Mayo Clinic College of Medicine, Rochester, MN, ⁵Pulmonary/Critical Care, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic small-vessel necrotizing vasculitis presenting with asthma and eosinophilia. Anti-neutrophil cytoplasmic antibodies (ANCA) association may influence…
Abstract Number: 2721 • 2018 ACR/ARHP Annual Meeting
Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden
Matina Liapi¹, David Jayne², Mårten Segelmark³ and Aladdin Mohammad⁴, ¹Medicine, Blekinge Hospital, Karlskrona, Sweden, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³Clinical Sciences, Nephrology, Lund University, Lund, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: To estimate the rate and predictors of venous thromboembolic events (VTEs) in a population-based cohort of patients with ANCA- associated vasculitis (AAV). Methods: 322…
Abstract Number: 2852 • 2018 ACR/ARHP Annual Meeting
Excessive Formation of Neutrophil Extracellular Traps: Different Role in the Pathogenesis of ANCA-Associated Vasculitis and Systemic Lupus Erythematosus
Laura van Dam¹, Tineke Kraaij¹, Sylvia W.A. Kamerling¹, Hans U. Scherer², Ton Rabelink¹, Cees van Kooten¹ and Y.K. Onno Teng¹, ¹Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: ANCA-associated vasculitis (AAV) and systemic lupus erythematosus (SLE) both cause glomerulonephritis with pauci-immune and full-house immunofluorescence patterns, respectively. Although AAV and SLE are clinically…
Abstract Number: 1753 • 2018 ACR/ARHP Annual Meeting
Interstitial Lung Disease in ANCA-Associated Vasculitis Defines a Unique Subgroup of Patients at High Risk for Respiratory Death: A Cluster Analysis
Zachary Wallace¹, Yuqing Zhang², John H. Stone³ and Hyon K. Choi⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³Home Address, Sudbury, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) has a propensity for heterogeneous organ involvement. ANCA specificity has increasingly been favored over clinical diagnosis (e.g., microscopic polyangiitis) for subgrouping…
Abstract Number: 2722 • 2018 ACR/ARHP Annual Meeting
Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results
Jens Rathmann¹, David Jayne², Goran Jönsson³, Mårten Segelmark⁴, Jan-Åke Nilsson⁵ and Aladdin Mohammad², ¹Rheumatology, Skanes University Hospital, Lund, Lund, Sweden, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Clinical Sciences, Nephrology, Lund University, Lund, Sweden, ⁵Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: To determine the incidence rates, predictors and outcome of severe infections in ANCA associated vasculitis (AAV). Methods: We conducted a population-based cohort study in…
Abstract Number: 2971 • 2018 ACR/ARHP Annual Meeting
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease: Long Term Outcomes
Joanna Tieu^1,2, Seerapani Gopaluni^3,4, Rona Smith¹ and David Jayne¹, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, University of Adelaide, Adelaide, Australia, ³Medicine, University of Cambridge, Cambridge, United Kingdom, ⁴Vasculitis and Lupus, Addenbrooke’s Hospital, Cambridge, United Kingdom
Background/Purpose: Despite a low incidence of hypogammaglobulinemia (HG) in clinical trials using rituximab (RTX), HG occurs in follow-up of patients with autoimmune disease. Immunoglobulin replacement…
Abstract Number: 1758 • 2018 ACR/ARHP Annual Meeting
A 24 Month Analysis of Rituximab Safety and Efficacy in Eosinophilic Granulomatosis with Polyangiitis
Vítor Teixeira^1,2, Aladdin Mohammad^1,3 and David Jayne¹, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Rheumatology Department, CHLN - Santa Maria Hospital, Lisbon Academic Medical Center, Lisbon, Portugal, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) frequently pursues a refractory course leading to high glucocorticoid exposure and toxicity. A previous retrospective study found rituximab (RTX)…
Abstract Number: 2725 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Long-Term Follow-up of 382 Microscopic Polyangiitis Patients
Yann Nguyen¹, Christian Pagnoux², Alexandre Karras³, Thomas Quémeneur⁴, Francois Maurier⁵, Mohamed Hamidou⁶, Alain Le Quellec⁷, Noémie Jourde-Chiche⁸, Pascal Cohen¹, Alexis Régent¹, François Lifermann⁹, Arsène Mékinian¹⁰, Chahéra Khouatra¹¹, Eric Hachulla¹², Jacques Ninet¹³, Jacques Pourrat¹⁴, Marc Ruivard¹⁵, Pascal Godmer¹⁶, Jean-Francois Viallard¹⁷, Benjamin Terrier¹, Luc Mouthon¹, Loïc Guillevin¹ and Xavier Puéchal¹, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, Paris, France, ⁴Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁵Médecine interne, Hôpitaux Privés de Metz, Metz, France, ⁶Department of Internal Medicine, CHU de Nantes, France, Nantes, France, ⁷Department of Internal Medicine, Hôpital Saint-Eloi, CHU de Montpellier, France, Montpellier, France, ⁸Nephrology, Department of Nephrology, AP-HM, CHU Conception, Marseille, France, Marseille, France, ⁹Dax, Dax, France, ¹⁰Department of Internal Medicine, Hôpital Saint-Antoine, APHP, Paris, France, Paris, France, ¹¹Department of Respiratory Medicine, National Reference Center for Rare Pulmonary Diseases, Hospices civils de Lyon, Hôpital Louis Pradel, Lyon, France, Lyon, France, ¹²Department of Internal Medicine, National Reference Center for Systemic Sclerosis, Hôpital Claude Huriez, CHRU Lille, France, Lille, France, ¹³Department of Internal Medicine, Hôpital Edouard Herriot HCL, CHU de Lyon, France, Lyon, France, ¹⁴Department of Nephrology, Hôpital de Rangueil, CHU Toulouse, France, Toulouse, France, ¹⁵Department of Internal Medicine, CHU Estang, Clermont-Ferrand, France, Clermont-ferrand, France, ¹⁶Department of Internal Medicine, CH Vannes, France, Vannes, France, ¹⁷Department of Internal Medicine, Hôpital Haut-Lévêque, Bordeaux, France, CHU Bordeaux, France
Background/Purpose: Microscopic polyangiitis (MPA) is a systemic ANCA-associated small-vessel necrotizing vasculitis characterized by general symptoms, and visceral manifestations, including rapidly progressive glomerulonephritis and alveolar hemorrhage.…
Abstract Number: 1761 • 2018 ACR/ARHP Annual Meeting
Evaluation of the Functional Activity of Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis
Ana Paula Toledo Del Rio¹, Stephanie Ospina Prieto¹, Bruno Kosa Lino Duarte¹, Manoel Barros Bertolo^1,2, Margareth de Castro Ozelo¹ and Zoraida Sachetto¹, ¹Internal Medicine, Faculty of Medical Science - State University of Campinas/Unicamp, Campinas, Brazil, ²INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil
Background/Purpose: ANCA-associated vasculitis (AAV) are relapsing diseases with high morbidity and mortality. The vascular damage present in these patients requires continuous repair with the participation…
Abstract Number: 2726 • 2018 ACR/ARHP Annual Meeting
Severe Infections in Systemic Necrotizing Vasculitis: Incidence and Risk Factors
Claudia Elizabeth Pena¹, Ana Carolina Costi², Lucila Garcia³, Mariana Pera⁴ and Mercedes Garcia¹, ¹Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ²Rheumatology Section, HIGA General San Martin La Plata, La Plata, Argentina, ³HIGA General San Martin La Plata, La Plata, Argentina, ⁴HIGA General San Martin La Plata, la plata, Argentina
Background/Purpose: Infections in patients with systemic necrotizing vasculitis represent one of the main causes of mortality. Risk factors of infection such as corticosteroid use, intensity…

« Previous Page
1
…
6
7
8
9
10
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].